Clinical trials
Myelofibrosis clinical trials
Below are recruiting myelofibrosis clinical trials, each written for real people, not researchers. We’re tracking 89 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04176198RecruitingPhase 1/Phase 2
Oral nuvisertib for myelofibrosis after JAK inhibitor failure
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
Birmingham, AlabamaAges 18 years+ - NCT06773195RecruitingPhase 1/Phase 2
Study of Ruxolitinib and Ulixertinib for Myelofibrosis
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Boston, MassachusettsAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT07551427RecruitingPhase 2
Testing TQ05105 for intermediate/high-risk myelofibrosis
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
Hefei, AnhuiAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT04942080Recruiting
Using CALR test results to track certain blood cancers
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
AngersAges 18 years+ - NCT05037760RecruitingPhase 2
Elritercept alone or with ruxolitinib for myelofibrosis
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
Concord, New South WalesAges 18 years+ - NCT05371964RecruitingPhase 1
Imetelstat plus ruxolitinib for myelofibrosis patients
This Phase 1 study tests whether imetelstat combined with ruxolitinib is safe and may improve disease activity in people with myelofibrosis. It is aimed at people who need symptom control and may be taking (or considered for) ruxolitinib.
Duarte, CaliforniaAges 18 years+ - NCT05535764RecruitingPhase 1
Test PegINFa after bone marrow transplant for myelofibrosis
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
Salt Lake City, UtahAges 18 years+ - NCT05710211Recruiting
Study of gene changes in ASXL1-mutated myelofibrosis
This study looks at how ASXL1 gene changes shape myelofibrosis over time. It may help doctors better understand the disease and potentially improve future treatments.
AngersAges 18 years+ - NCT05731245RecruitingPhase 2
Ropeginterferon for early myelofibrosis with low-to-mid risk
This Phase 2 trial studies ropeginterferon alfa-2b (a type of interferon medicine) in adults with early, lower-risk myelofibrosis. The goal is to see if it can control the disease better or improve outcomes with an acceptable safety profile.
Taipei, Taiwan, 100Ages 20 years+ - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT06122831RecruitingPhase 1/Phase 2
TQ05105 and TQB3617 for myelofibrosis
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
Guangzhou, GuangdongAges 18 years+ - NCT06151119Recruiting
PET scan test for myelofibrosis using a special tracer
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
Xiamen, FujianAges 18 years+ - NCT06164561Recruiting
FAPI PET/MRI scan for myelofibrosis
This trial tests whether a special type of PET scan (using a tracer called 18F-FAPI) can see myelofibrosis activity better than standard scans. It may help doctors track the disease more accurately without needing extra biopsies.
Hangzhou, ZhejiangAges 18–80 - NCT06345495RecruitingPhase 2
High-dose ruxolitinib and stem cell transplant for enlarged spleen in myelofibrosis
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Houston, TexasAges 18–75 - NCT06397313RecruitingPhase 2
New drug for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
BolognaAges 18 years+ - NCT06414681RecruitingEarly Phase 1
Tagraxofusp and pacritinib for myelofibrosis after JAK inhibitor
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
Fairway, KansasAges 18 years+ - NCT06533813Recruiting
Studying health outcomes in people with myelofibrosis
This study collects information from people diagnosed with myelofibrosis to understand how the disease affects them over time. It may help researchers learn more about the condition and improve future care.
YerevanAges 18–100 - NCT06605586RecruitingPhase 1/Phase 2
Test of tasquinimod for myelofibrosis that stopped responding to JAK inhibitor therapy
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
AachenAges 18 years+ - NCT06674382Recruiting
Half-matched stem cell transplant for myelofibrosis
This trial tests whether a stem cell transplant from a half-matched (haploidentical) donor can help people with myelofibrosis. You might join if you don't have a fully matched sibling or unrelated donor.
BeijingAges Any age - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06781099Recruiting
Iron removal machine for MDS or myelofibrosis with high iron
This trial tests a new way to remove extra iron from the blood using a machine (like dialysis). It is for people with myelodysplastic syndrome or myelofibrosis who have severe anemia, high iron levels, and cannot take standard iron-removal pills or injections.
Oullins-Pierre-BéniteAges 18 years+ - NCT06887803RecruitingPhase 1/Phase 2
Roginolisib plus ruxolitinib for myelofibrosis not helped by JAK inhibitors
This trial tests a new combination of two drugs, roginolisib and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough with ruxolitinib alone. It aims to see if adding roginolisib can improve symptoms and spleen size.
Florence, FlorenceAges 18 years+
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myelofibrosis?
- Yes. Clin2 currently lists 89 recruiting myelofibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myelofibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.